Axon Therapies Announces Positive Results From First-In-Human Clinical Study in Late-Breaking Clinical Trial Session At 2020 Virtual HFSA Conference

Interim results from Axon Therapies’ First-in-Human Trial of the Satera Ablation System (11 HFpEF patients at 1- and 3-month follow-up)

Interim results from Axon Therapies’ First-in-Human Trial of the Satera Ablation System (11 HFpEF patients at 1- and 3-month follow-up)

NEW YORK, Oct. 9, 2020 /PRNewswire/ — Axon Therapies, a Coridea portfolio company focused on addressing one of the root causes of heart failure, today announced positive interim results from their first-in-human (FIH) trial of splanchnic ablation for volume management, or SAVM, using the Satera™ Ablation System. Dr. Sanjiv Shah, Director of the HFpEF program at Northwestern University Feinberg School of Medicine in Chicago, IL presented the results during the Late Breaking Clinical Trial session at the annual Heart Failure Society of America (HFSA) meeting.

“As physicians, we are often limited in our ability to adequately decongest heart failure patients and prevent excessive increases in pressure during exertion. Although research has shown that inappropriate volume redistribution is a major contributor to functional limitations and outcomes, no interventions targeting this mechanism have existed until now,” stated cardiologist Dr. Sanjiv Shah. “I’m very excited about the positive first-in-human results from Axon’s innovative ablation technology. The SAVM procedure selectively blocks the neural pathway carrying signals from the chronically active sympathetic system to the splanchnic vascular bed, causing selective venodilation, improved venous compliance, and ultimately restoring appropriate volume balance within the circulation.”

A total of 11 heart failure patients with preserved ejection fraction (HFpEF) were successfully treated using Axon’s Satera™ Ablation System. Interim data was presented on 1- and 3-month follow-up post-procedure. Endpoints included a composite safety index, New York Heart Association (NYHA) Heart Failure classification, Kansas City Cardiomyopathy Questionnaire (KCCQ) score, and 6-minute walk test.

Study highlights include:

  • Achieved procedural success in all 11 patients with no device or procedural-related serious adverse events (SAEs)
  • Significant improvement in NYHA classification (p<0.05) at both 1-month and 3-month follow-up
  • Significant improvement in KCCQ score (p<0.05) at both 1-month (43 vs. 64) and 3-month (43 vs. 79) follow-up
  • Significant improvement in 6-minute walk test (p<0.05) at both 1-month (293 vs. 342 meters) and 3-month (293 vs. 347 meters) follow-up
  • Significant reduction in NT-proBNP (p<0.05) at 3-month (1,292 vs. 627 pg/mL) follow-up

Building on the FIH results, Axon is initiating REBALANCE-HF, a prospective, randomized, sham controlled, double-blinded feasibility IDE trial in early 2021. The study will enroll 80 patients at up to 20 sites to assess the safety and efficacy of SAVM using the Satera Ablation System in HFpEF patients. Learn more at[1].

“The SAVM procedure is a frontline heart failure therapy that restores volume balance, stops disease progression and improves outcomes in heart failure patients,” commented Howard Levin MD, CEO of Axon Therapies. “In addition, the outpatient, transvenous procedure is implant-free, which preserves future options for the patient. We are initially focusing on the underserved HFpEF patient population, but believe SAVM, with the Satera Ablation System, may have applications for all heart failure patients in the future.”

About Axon Therapies, Inc.
Axon Therapies, a portfolio company of proven medtech incubator Coridea[2], is focused on solutions to address one of the root causes of heart failure. Developed from a known surgical procedure, splanchnic ablation for volume management (SAVM) using the Satera™ Ablation System enables selective and sustained venodilation of the splanchnic bed. During the procedure the right greater splanchnic nerve is ablated and signals to the chronically hyperactive sympathetic nervous system (SNS) are disrupted. This allows the body to restore normal volume balance, stop disease progression and improve symptoms in heart failure patients. Learn more at[3].

View original content to download multimedia:[4]

SOURCE Axon Therapies, Inc.

1 2 3